Company / SG&A Expense
Tandem Diabetes Care SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$445.0M
FY2025
5-year range
$165.7M / $445.0M
FY2021-FY2025
Trend
+14.2%
vs FY2024
Sector context
#72 of 158
Health Care
What the data says
At $445M, Tandem Diabetes Care's sg&a expense ranks #87 of 158 in the Health Care sector. SG&A Expense has increased for 8 consecutive years, from $79M in FY2017 to $445M in FY2025.
Based on SEC 10-K filings.
$445M in FY2025 with a 5-year CAGR of +33.4%.
Increased from $353M to $445M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +29.5%
- 5-Year CAGR
- +33.4%
- 10-Year CAGR
- -
Sector benchmark
#87 of 158 in Health CareTop 54% of 158This company $445.0M Sector average $175.9B
▼
-99.7% below sector average
Key checks
Key Insights
- Tandem Diabetes Care's sg&a expense has grown for 8 consecutive years.
- 5-year CAGR of +33.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 14.2% year-over-year.
- Ranks #72 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $445.0M | +14.2% |
| FY2024 | $389.8M | +10.6% |
| FY2023 | $352.5M | +72.0% |
| FY2022 | $204.9M | +23.6% |
| FY2021 | $165.7M | +57.5% |
| FY2020 | $105.2M | +21.8% |
| FY2019 | $86.4M | +4.3% |
| FY2018 | $82.8M | +5.4% |
| FY2017 | $78.6M | -5.1% |
| FY2016 | $82.8M | +5.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026